DavidWOslinMD

Addiction, Psychopharmacology, Integrative Psychiatry, Clinical Pharmacology

Professor of Psychiatry Staff Physician, Philadelphia Veterans Administration Medical Center, Philadelphia, PA; Director, VISN 4 Mental Illness, Research, Education and Clinical Center (MIRECC), Philadelphia Veterans Administration Medical Center, Philadelphia, PA; Chief of Behavioral Health, Philadelphia VA Medical Center, Philadelphia, PA, Department: Psychiatry.

Join to view full profile

Dr. Oslin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Oslin's full profile

Already have an account?

Office
3900 Woodland Ave
Philadelphia, PA 19104
Phone+1 215-823-5894

Summary

Dr. David Oslin is a psychiatrist in Philadelphia, PA and is affiliated with multiple hospitals in the area, including Philadelphia Veterans Affairs Medical Center and Hospital of the University of Pennsylvania. He received his medical degree from University of Virginia School of Medicine and has been in practice 28 years. He specializes in addiction and geriatric psychiatry and is experienced in health services accessibility and clinical trials as topic.

Education & Training

University of Pennsylvania Health SystemResidency, Psychiatry, 1994 - 1996
University of Maryland/Sheppard PrattResidency, Psychiatry, 1990 - 1994
University of Virginia School of MedicineClass of 1989

Certifications & Licensure

PA State Medical License 1994 - 2024
MD State Medical License 1991 - 1995
American Board of Psychiatry and Neurology Psychiatry

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Treating Alcohol Use In Older Adults With Depression Start of enrollment: 1999 Oct 01
Completed
Phase 4
Managing Alcoholism in People Who Do Not Respond to Naltrexone Start of enrollment: 2003 Sep 01
Completed
Phase 4
Telephone Disease Management At-Risk Drinking (TDM II) Start of enrollment: 2004 Jan 01
Completed
Not Applicable
Endophenotype for Alcohol Misuse in Healthy Minority Populations Start of enrollment: 2005 Nov 01
Completed
Phase 4
A Randomized Clinical Trial of Alcohol Care Management Start of enrollment: 2007 Aug 01
Completed
Phase 4
Understanding Treatment Response With Naltrexone Among White Alcoholics Start of enrollment: 2007 Dec 01
Completed
Phase 4
Pharmacogenetic Response to Naltrexone For Alcohol Dependence Start of enrollment: 2009 Jan 05
Completed
Phase 4
Integrated vs Sequential Treatment for PTSD and Addiction Start of enrollment: 2011 Feb 01
Completed
Not Applicable
Reducing the Burden of Depression Related Disability Start of enrollment: 2014 May 19
Completed
Not Applicable
The PACE/PACENET Behavioral Health Laboratory Project Start of enrollment: 2010 Aug 01
Completed
Not Applicable
Evaluation of the PACE/PACENET BHL Clinical Program Start of enrollment: 2014 Mar 01
Enrolling by invitation
Topiramate Treatment of Alcohol Use Disorders in African Americans Start of enrollment: 2017 Aug 01
Terminated
Phase 4
PRIME Care (PRecision Medicine In MEntal Health Care) 2.0 Start of enrollment: 2020 Jun 02
Recruiting
Phase 4
Roles: Contact, Principal Investigator
VA Aripiprazole vs Esketamine for Treatment Resistant Depression Start of enrollment: 2023 Oct 27
Withdrawn
Phase 4
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

11 citations
Addressing Common Challenges in the Implementation of Collaborative Care for Mental Health: The Penn Integrated Care Program.
Courtney Benjamin Wolk, Cecilia Livesey, Maria A. Oquendo, Matthew J. Press, David S. Mandell
Annals of Family Medicine. 2021-03-01
91 citations
Variation in Nicotinic Acetylcholine Receptor Genes is Associated with Multiple Substance Dependence Phenotypes
Richard Sherva, Henry R. Kranzler, Yi Yu, Mark W. Logue, James Poling
Neuropsychopharmacology. 2010-05-19
417 citations
A Functional Polymorphism of the μ -Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients
David W. Oslin, Wade H. Berrettini, Henry R. Kranzler, Helen M. Pettinati, Joel Gelernter
Neuropsychopharmacology. 2003-06-18

Lectures

American Psychiatric Association Publishing
American Association for Geriatric Psychiatry (AAGP), Los Angeles, California - 3/14/2013
8th Annual PADRECC/MIRECC Symposium on Neurodegenerative Diseases
Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania - 11/9/2012

Press Mentions

Genetic Testing Could Help Match People with the Right Antidepressant, New VA Study FindsJuly 12th, 2022
Does Pharmacogenomic Testing Improve Outcomes in Major Depressive Disorder?July 12th, 2022
Pharmacogenetic Testing Could Improve Outcomes for Patients with DepressionJuly 12th, 2022
Join now to see all

Grant Support

Pharmacogenetic Response To Naltrexone For Alcohol DependenceNational Institute On Alcohol Abuse And Alcoholism2008–2011
Nrsa Training: Psychiatric-Medical Comorbidity In AgingNational Institute Of Mental Health2006–2010
Defining An Endophenotype For Opioid Dysregulation: A Pilot StudyNational Institute On Alcohol Abuse And Alcoholism2008–2009
Genetic Contributions To Treatment ResponseNational Institute On Drug Abuse2004–2008
Non-Response To NTX Next Steps In Managing AlcoholismNational Institute On Alcohol Abuse And Alcoholism2003–2007
Depression And Medical Care:Aging And Clinical SettingNational Institute Of Mental Health2006
Treatment Of LATE Life Depression Complicated By AlcoholNational Institute Of Mental Health1999–2003